This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

August 31, 2026
5 min

The Medicine Maker

At a Glance

Category	Detail
Condition	CAR T-cell therapy
Key Mechanisms	Automated manufacturing processes and gene editing technologies
Target Population	Patients requiring CAR T-cell therapy and gene therapy for sickle cell disease
Care Setting	Clinical trials and commercial manufacturing

Key Highlights

Bristol Myers Squibb ends partnership with Cellares for Breyanzi manufacturing.
Sickle cell gene therapy shows faster collection and modification of stem cells.
Regnase-1 gene deletion enhances CAR T cell efficacy against osteosarcoma.
CD40 stimulation improves CAR T activity in solid tumors.
Bioinspired nanoparticles effectively deliver cholesterol gene editing.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Patients with sickle cell disease and solid tumors

Innovative therapies are being developed to enhance CAR T-cell efficacy and gene editing.

Clinical Best Practices

Evaluate automated manufacturing processes for CAR T-cell therapies.
Consider gene therapy approaches for sickle cell disease.
Investigate genetic modifications to improve immune responses in CAR T-cell therapies.